

Resource Summary Report

Generated by [dkNET](#) on Sep 4, 2026

BEL-7404

RRID:CVCL_6568

Type: Cell Line

Proper Citation

RRID:CVCL_6568

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_6568

Proper Citation: RRID:CVCL_6568

Description: Cell line BEL-7404 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Human papillomavirus-related endocervical adenocarcinoma

Defining Citation: [PMID:6154311](#), [PMID:6275024](#), [PMID:11774261](#), [PMID:23505090](#), [PMID:28807831](#)

Comments: Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3131C0001000700064). It was the sole source for the STR profile of this entry., Population: African American., Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=28807831). Originally thought to originate from a 69 year old male patient with a hepatocellular carcinoma..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: BEL-7404

Synonyms: Bel-7404, BEL 7404, Bel 7404, BEL7404, Bel7404, 7404

Cross References: BTO:BTO_0005814, ChEMBL-Cells:ChEMBL3307908, ChEMBL-Targets:ChEMBL614280, GEO:GSM743502, GEO:GSM936755, GEO:GSM1374401, PubChem_Cell_line:CVCL_6568, Wikidata:Q54795973

ID: CVCL_6568

Hierarchy: cvcl_0030

Record Creation Time: 20220427T215358+0000

Record Last Update: 20260904T021634+0000

Ratings and Alerts

No rating or validation information has been found for BEL-7404.

Warning: Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=28807831). Originally thought to originate from a 69 year old male patient with a hepatocellular carcinoma.

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00550.

Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3131C0001000700064). It was the sole source for the STR profile of this entry.,

Population: African American., Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=28807831). Originally thought to originate from a 69 year old male patient with a hepatocellular carcinoma..

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 114 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Xiao C, et al. (2025) Pharmacological targeting of large tumor suppressor kinases (LATS) 1 and 2 augments tissue repair and regeneration. British journal of pharmacology.

Zhang C, et al. (2024) Re-evaluation of the relationship between PrPc expression and patient prognosis in primary esophageal squamous cell carcinoma and primary hepatocellular carcinoma. Scientific reports, 14(1), 31122.

He Z, et al. (2024) Invention of circRNA promoting RNA to specifically promote circRNA production. Nucleic acids research, 52(17), e83.

Tang FF, et al. (2023) Network pharmacological analysis of corosolic acid reveals P4HA2 inhibits hepatocellular carcinoma progression. BMC complementary medicine and therapies, 23(1), 171.

Qian X, et al. (2023) Preoperative fibrinogen is associated with the clinical survival of primary liver cancer patients and promotes hepatoma metastasis via the PTEN/AKT/mTOR pathway. Heliyon, 9(6), e16696.

Jia T, et al. (2023) circSOX4 Enhances Hepatocellular Carcinoma Progression via miR-218-5p/YY1 Signaling. *BioMed research international*, 2023, 3370440.

Wu Y, et al. (2023) Role of DEP domain-containing protein 1B (DEPDC1B) in epithelial ovarian cancer. *Journal of Cancer*, 14(5), 784.

Yao J, et al. (2023) lncRNA PITPNA-AS1 promotes cell proliferation and metastasis in hepatocellular carcinoma by upregulating PDGFD. *Aging*, 15(10), 4071.

Weiskirchen R, et al. (2023) Research reporting guidelines for cell lines: more than just a recommendation. *Annals of translational medicine*, 11(12), 421.

Ding J, et al. (2022) Facile Synthesis of NaYF₄:Yb Up-Conversion Nanoparticles Modified with Photosensitizer and Targeting Antibody for In Vitro Photodynamic Therapy of Hepatocellular Carcinoma. *Journal of healthcare engineering*, 2022, 4470510.

Bao H, et al. (2022) A Pan-Cancer Analysis of UBE2S in Tumorigenesis, Prognosis, Pathway, Immune Infiltration and Evasion, and Therapy Response from an Immune-Oncology Perspective. *Journal of oncology*, 2022, 3982539.

Niu Z, et al. (2022) MCT4 Promotes Hepatocellular Carcinoma Progression by Upregulating TRAPPC5 Gene. *Journal of hepatocellular carcinoma*, 9, 289.

She P, et al. (2022) Pixantrone Sensitizes Gram-Negative Pathogens to Rifampin. *Microbiology spectrum*, 10(6), e0211422.

Liu S, et al. (2022) Effects of circFOXO3 on the Proliferation and Invasion of Liver Cancer Cells by Regulating PI3K/Akt Pathway. *Contrast media & molecular imaging*, 2022, 2109908.

Zhao M, et al. (2022) The upregulation of stromal antigen 3 expression suppresses the phenotypic hallmarks of hepatocellular carcinoma through the Smad3-CDK4/CDK6-cyclin D1 and CXCR4/RhoA pathways. *BMC gastroenterology*, 22(1), 378.

Yuan D, et al. (2022) Knockdown of RSPH14 inhibits proliferation, migration, and invasion and promotes apoptosis of hepatocellular carcinoma via RelA. *Cancer cell international*, 22(1), 129.

Chen Y, et al. (2022) Long non-coding RNA HOXB-AS1 is a prognostic marker and promotes hepatocellular carcinoma cells' proliferation and invasion. *Open life sciences*, 17(1), 944.

Gou Y, et al. (2022) Polysaccharides Produced by the Mushroom *Trametes robiniophila* Murr Boosts the Sensitivity of Hepatoma Cells to Oxaliplatin via the miR-224-5p/ABCB1/P-gp Axis. *Integrative cancer therapies*, 21, 15347354221090221.

Tang Y, et al. (2022) Network pharmacology identification and in Vivo validation of key pharmacological pathways of *Phyllanthus reticulatus* (Euphorbiaceae) leaf extract in liver cancer treatment. *Journal of ethnopharmacology*, 297, 115479.

Huang J, et al. (2022) NOL12 as an Oncogenic Biomarker Promotes Hepatocellular Carcinoma Growth and Metastasis. *Oxidative medicine and cellular longevity*, 2022, 6891155.